Dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduces liver fat content (LFC) and improves γ-glutamyl transpeptidase (GGT) levels in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), when used in combination with standard T2D treatment, a randomized controlled trial (RCT) published in Diabetologia found. Dulaglutide is currently approved for the improvement of glycemic control in individuals with T2D and for the reduction of major adverse cardiovascular events in adults with T2D, with and without established cardiovascular disease.
NAFLD is common among individuals with T2D, while “the presence of T2D in individuals with NAFLD is a risk factor for its progression to non-alcoholic steatohepatitis (NASH), a severe form of NAFLD that can further progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma,” the…
